F
Fabian Schmidt
Researcher at Rockefeller University
Publications - 66
Citations - 10771
Fabian Schmidt is an academic researcher from Rockefeller University. The author has contributed to research in topics: Antibody & Biology. The author has an hindex of 22, co-authored 50 publications receiving 4923 citations. Previous affiliations of Fabian Schmidt include Aaron Diamond AIDS Research Center & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host.
Fabian Schmidt,Brandon F. Keele,Gregory Q. Del Prete,Dennis Voronin,Christine M. Fennessey,Steven J. Soll,Melissa Kane,Alice Raymond,Robert J. Gifford,Vineet N. KewalRamani,Jeffrey D. Lifson,Paul D. Bieniasz,Paul D. Bieniasz,Theodora Hatziioannou +13 more
TL;DR: An HIV-1–based molecular clone is derived that can cause AIDS in monkeys after transient CD8+ cell depletion during acute infection, and this clone is used to identify the role of species-specific adaptations.
Journal ArticleDOI
Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
Frauke Muecksch,Helen Wise,Kate Templeton,Becky Batchelor,Marilyn Squires,Kirsty McCance,Lisa Jarvis,Kristen Malloy,Elizabeth Furrie,Claire Richardson,Jacqueline MacGuire,Ian M Godber,Alana M. Burns,S. Mavin,Fengwen Zhang,Fabian Schmidt,Paul D. Bieniasz,Sara Jenks,Theodora Hatziioannou +18 more
TL;DR: Quantitative measurements generated by serological assays based on the spike protein were better at predicting neutralising antibody titres than those based on nucleocapsid, but performance was variable, and manufacturer positivity thresholds were not able to predict the presence or absence of detectable neutralising activity.
Posted ContentDOI
Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2
Fred D. Mast,Peter C. Fridy,Natalia E. Ketaren,Jiayi Wang,Erica Y. Jacobs,Jean Paul Olivier,Tanmoy Sanyal,Kelly R. Molloy,Fabian Schmidt,Magdalena Rutkowska,Yiska Weisblum,L.M. Rich,E. R. Vanderwall,Nicholas Dambrauskas,Vigdorovich,Sarah Keegan,Jiler Jb,Stein Me,Olinares Pdb,Theodora Hatziioannou,D. N. Sather,D. N. Sather,Jason S. Debley,Jason S. Debley,Jason S. Debley,David Fenyö,Andrej Sali,Paul D. Bieniasz,Paul D. Bieniasz,John D. Aitchison,John D. Aitchison,Brian T. Chait,Michael P. Rout +32 more
TL;DR: In this paper, the authors presented a large repertoire of high affinity nanobodies against SARS-CoV-2 Spike protein with excellent kinetic and viral neutralization properties, which can be strongly enhanced with oligomerization.
Journal ArticleDOI
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
Alice Cho,Frauke Muecksch,Zhijun Wang,Tarek Ben Tanfous,Justin DaSilva,Raphael Raspe,B J Johnson,Eva Bednarski,Victor Ramos,Dennis Schaefer-Babajew,Irina Shimeliovich,Juan Dizon,Kai-Hui Yao,Fabian Schmidt,Katrina G. Millard,Martina Turroja,Mila Jankovic,Thiago Y. Oliveira,Anna Gazumyan,Christian Gaebler,Marina Caskey,Theodora Hatziioannou,Paul D. Bieniasz,Michel C. Nussenzweig +23 more
TL;DR: The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective, and why the Janssen vaccine appears to have been less protective against severe disease during the Omicron surge than the mRNA vaccine.
Journal ArticleDOI
Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection.
Rachel A. Liberatore,Rachel A. Liberatore,Emily J Mastrocola,Emily J Mastrocola,Elena Cassella,Fabian Schmidt,Jessie R Willen,Jessie R Willen,Dennis Voronin,Trinity Zang,Trinity Zang,Theodora Hatziioannou,Paul D. Bieniasz,Paul D. Bieniasz +13 more
TL;DR: A chimeric Rhabdo-Immunodeficiency virus (RhIV) murine model is described that recapitulates key features of HIV-1 entry, tropism and antibody sensitivity, and enables the convenient in vivo study of AIDS-1 Env-receptor interactions, antiviral activity of antibodies and humoral responses against HIV- 1 Env, in a genetically manipulatable host.